PubMed=9920784; DOI=10.1006/bbrc.1998.9968
Mori T., Fukuda Y., Kuroda H., Matsumura T., Ota S., Sugimoto T., Nakamura Y., Inazawa J.
Cloning and characterization of a novel Rab-family gene, Rab36, within the region at 22q11.2 that is homozygously deleted in malignant rhabdoid tumors.
Biochem. Biophys. Res. Commun. 254:594-600(1999)

PubMed=10417765; DOI=10.1002/(SICI)1097-0215(19990827)82:5<678::AID-IJC10>3.0.CO;2-K
Sugimoto T., Hosoi H., Horii Y., Ishida H., Mine H., Takahashi K., Abe T., Ohta S., Sawada T.
Malignant rhabdoid-tumor cell line showing neural and smooth-muscle-cell phenotypes.
Int. J. Cancer 82:678-686(1999)

PubMed=15355927; DOI=10.1158/1078-0432.CCR-04-0192
Kuwahara Y., Hosoi H., Osone S., Kita M., Iehara T., Kuroda H., Sugimoto T.
Antitumor activity of gefitinib in malignant rhabdoid tumor cells in vitro and in vivo.
Clin. Cancer Res. 10:5940-5948(2004)

PubMed=18281554; DOI=10.1158/1078-0432.CCR-07-1661
Katsumi Y., Kuwahara Y., Tamura S., Kikuchi K., Otabe O., Tsuchiya K., Iehara T., Kuroda H., Hosoi H., Sugimoto T.
Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the cytotoxicity.
Clin. Cancer Res. 14:1192-1199(2008)

PubMed=21871868; DOI=10.1016/j.bbrc.2011.08.047; PMCID=PMC3214763
Katsumi Y., Iehara T., Miyachi M., Yagyu S., Tsubai-Shimizu S., Kikuchi K., Tamura S., Kuwahara Y., Tsuchiya K., Kuroda H., Sugimoto T., Houghton P.J., Hosoi H.
Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression.
Biochem. Biophys. Res. Commun. 413:62-68(2011)

CLPUB00599
Sugimoto T., Kuroda H., Kuwahara Y., Katsumi Y., Misawa A., Moritake H., Hosoi H.
Cellular and molecular characteristics of established childhood soft-tissue sarcoma cell lines.
J. Cancer Res. Therap. Oncol. 7:202.1-202.12(2019)